Microsoft strongly encourages users to switch to a different browser than Internet Explorer as it no longer meets modern web and security standards. Therefore we cannot guarantee that our site fully works in Internet Explorer. You can use Chrome or Firefox instead.

Chemocentryx Inc. sell geldnutzer

Start price
30.07.21 / 60%
Target price
Performance (%)
This prediction is currently active. The SELL prediction by geldnutzer currently has a performance of 13.08%. This prediction currently runs until 30.07.22. The prediction end date can be changed by geldnutzer at any time. geldnutzer has 60% into this prediction
Performance without dividends (%)
Name 1w 1m
Chemocentryx Inc. 8.397% 8.397%
iShares Core DAX® -0.333% -2.490%
iShares Core MSCI World 0.137% 0.148%
iShares Nasdaq 100 0.109% 2.019%
iShares S&P 500 0.469% -0.180%

According to geldnutzer what are the pros and cons of Chemocentryx Inc. for the foreseeable future?

Could be worthwhile Investment >10% per year
Revenue growth >5% per year expected
EBIT growth >5% per year expected
Fair valuation
Valuable balance sheet
ROE higher than 10% per year
Capable Management
Good culture
Future proof or reliable business model
Lower EBIT Margin than peer group
Very low/no dividend yield expected
negative Cash Flow expected
Bad rating
Little Investments for future growth
Increased challenges to pay loans and raise capital
Few uniques
Dependend from some customers or products
Growths slower than the competition
Sustainability is little important
high free float
Higher risks for its business
Below average Marketposition
Significant cyclical dependencies
Little known brand

Comments by geldnutzer for this prediction

In the thread Chemocentryx Inc. diskutieren
Prediction Sell
Perf. (%) 13.08%
Target price 10.000
Ends at 30.07.22

Sell mit Kursziel 10,0

Stopped prediction by geldnutzer for Chemocentryx Inc.

Chemocentryx Inc.

Start price
Target price
Perf. (%)

Could be worthwhile Investment >10% per year
Revenue growth >5% per year expected
EBIT growth >5% per year expected
Lower EBIT Margin than peer group